Severe smoking related to atrophy in Alzheimer’s brain regions

Last study in He studied the relationship between smoking and brain atrophy and whether the body mass indicator (BMI) affects this connection. The study showed that smokers had much lower gray and white brain volume than non -smokers. When BMI was included in statistical models, the relationship between the year of smoking and the loss of brain volume was reduced, which suggests an intermediary effect, not direct causes.

Neurodegenerative disorder: dissemination and risk factors

Neurodegenerative disorder occurs when nerve cells in the brain and nervous system They gradually lose their function, causing a decrease in physical and cognitive abilities. Alzheimer’s (AD) disease is the most common type of dementia, memory, cognitive function and behavior.

Increased dissemination of dementia has been recorded all over the world. The last study estimated that dementia was diagnosed with about 47 million people around the world. It is expected that this number will increase by 10 million new cases each year.

In many studies, early, medium and late life risk factors have been identified. Smoking is a risk factor that contributes to 14% of dementia around the world. Toxins present in cigarette smoke can cause neuroinitis, a mechanism closely associated with AD. In addition to dementia, previous studies have also shown that cigarette smokers are exposed to high risk of many diseases, such as cerebrospinal diseases and respiratory complaints.

While earlier meta -analyzes associated smoking with an increased risk of dementia, little studies have been examined on a large scale how the history of smoking and intensity directly relates to the imaging of the brain magnetic resonance imaging (MRI), and biomarker neurodegeneration. To assess this, the relationship between smoking and brain atrophy and the loss of brain tissue should be assessed before shrinking or death of neurons with reduced neuronal connections.

Scientists generally follow brain atrophy for AD and other neurodegenerative disorders by neuroimaging by losing volume in weighted structural imaging T1, which differs from aging. MRI is carried out to assess the loss of brain volume, biomarker of neurodegeneration.

Few studies on a large scale examined the relationship between smoking and brain atrophy based on the loss of brain volume to MRI, which can play a key role in determining how smoking contributes to the cognitive inheritance and ad.

About the study

The current study tested the hypothesis that people with smoking history experience higher brain atrophy at the level of the entire brain and regional levels of Lobar than non -smokers.

For this study, 10,134 participants from four research places aged 18 to 97 were selected. All participants underwent MRI scanning without the contrast of the whole body. Before imaging, they filled the questionnaires from which they were obtained demographic information, medical history and smoking. Each participant provided information on the number of packages they smoked a day and the number of years they burned.

Based on the answers to the questionnaire, the participants were grouped as a group of smoking (non-zero of the year) and a group of non-smoking (zero packages years). The packages correspond to the measure of tobacco to assess the history of smoking and the associated risk. The smoking group consisted of 3,292 participants, while the non -smoking group consisted of 6,842 people.

The current study uses the FastSurfer network, a widely verified deep learning pipeline, to quantitative assessment of brain volume from 3D T1 scans. The deep learning model was also applied to segmentation of intracranial volume (ICV).

Smokers conducted a regression analysis to examine the relationship between the years of smoking and the brain regions in two different models: Model 1 (corrected by age, gender and research place) and model 2 (corrected by age, gender, place and BMI).

Research results

Compared to the non -smoking group, the participants belonging to the smoking group were more often women, Caucasian, had higher BMI, were older and had higher indicators of type 2 diabetes and hypertension. The smoking group had an average year to 11.93.

Regional group comparisons revealed lower brain volume in smoking groups compared to non -smoking groups. Pearson’s two -dimensional correlation indicated a slight positive correlation between the higher BMI and the increased smoking years. Comparing Model 1 and Model 2, the current study observed the weakening of statistical significance and the size of the effects in 11 areas of the brain, when BMI was added, suggesting possible, but not proven, mediating BMI influence in the connection between the growth of smoking years and reduced brain volumes.

Importantly, smokers still showed significant atrophy in many regions, including areas associated with Alzheimer’s disease, such as hippocampus, rear rim and preuneus, even when adapting to BMI.

Conclusions

The current study revealed that people with smoking history and higher years of smoking had brain atrophy. Preliminary findings also indicate that BMI may play a potential and exploratory role in the connection between smoking cigarettes and the loss of brain volume. Therefore, obesity and smoking are two risk factors that can be used in the future to prevent dementia, including AD.

In the future, further research is necessary to examine the potential intermediary effects of the volume of the hyperintensiveness of the white being and the brain atrophy regarding the history of smoking and the years of parcels.

The key strength of this study is to analyze a large cohort with the history of smoking and quantitative structural imaging of the brain. In addition, it enabled measuring the regional volume of the brain threatened with AD pathology, such as hippocampus, rear rims and preuuneus.

Despite the strengths, the cross -sectional project limited the authors’ ability to end the causal relationship. The study project lacked the time resolution necessary for reliable mediation or moderation tests. In addition, the study did not include cognitive tests or alzheimer biomarkers, such as amyloid or tau, which limits the ability to directly observed the observed observed brain atrophy with dementia. Therefore, the role of BMI in the connection between smoking and brain atrophy requires more longitudinal analysis of validation.

Download a PDF copy now!